BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Treatment
184 results:

  • 1. The mechanisms behind the dual role of long non-coding RNA (lncRNA) metastasis suppressor-1 in human tumors: Shedding light on the molecular mechanisms.
    Abdullaev B; Alsaab HO; Hjazi A; Alkhafaji AT; Alawadi AH; Hamzah HF
    Pathol Res Pract; 2024 Apr; 256():155189. PubMed ID: 38452581
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prioritization of Fluorescence In Situ Hybridization (FISH) Probes for Differentiating Primary Sites of Neuroendocrine Tumors with Machine Learning.
    Pietan L; Vaughn H; Howe JR; Bellizzi AM; Smith BJ; Darbro B; Braun T; Casavant T
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139230
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
    Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
    Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.
    Ikezawa K; Urabe M; Kai Y; Takada R; Akita H; Nagata S; Ohkawa K
    Jpn J Clin Oncol; 2024 Mar; 54(3):271-281. PubMed ID: 38109477
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Reconsidering resectable oncological conditions in pancreatic tail cancer: A multicenter retrospective study on prognostic factors in pancreatic tail cancer after resection (HOPS Pt-01).
    Kimura Y; Nakamura T; Imamura M; Nagayama M; Murakami T; Hayashi T; Kato T; Tanaka K; Yoshida M; Kukita K; Imai K; Yoshida M; Masaki Y; Motoya M; Kuwatani M; Koyama M; Ohnishi H; Takemasa I
    Pancreatology; 2024 Feb; 24(1):109-118. PubMed ID: 38103948
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Screening for pancreatic cancer Among High-Risk Populations.
    Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
    JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular.
    Li O; Li L; Sheng Y; Ke K; Wu J; Mou Y; Liu M; Jin W
    Cancer Lett; 2023 Oct; 574():216391. PubMed ID: 37714257
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mutation Analysis of pancreatic Juice and Plasma for the Detection of pancreatic cancer.
    Levink IJM; Jansen MPHM; Azmani Z; van IJcken W; van Marion R; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685923
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Screening of Exosome-Derived Proteins and Their Potential as Biomarkers in Diagnostic and Prognostic for pancreatic cancer.
    Marin AM; Batista M; Korte de Azevedo AL; Bombardelli Gomig TH; Soares Caldeira Brant R; Chammas R; Uno M; Dias Araújo D; Zanette DL; Nóbrega Aoki M
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628784
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma.
    Ashina S; Masuda A; Yamakawa K; Hamada T; Tsujimae M; Tanaka T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Harada Y; Miki M; Juri N; Irie Y; Kanzawa M; Itoh T; Inoue J; Imai T; Fukumoto T; Kodama Y
    J Gastroenterol; 2023 Oct; 58(10):1055-1067. PubMed ID: 37477731
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Geographical, ethnic, and genetic differences in pancreatic cancer predisposition.
    Liew SZH; Ng KW; Ishak NDB; Lee SY; Zhang Z; Chiang J; Ngeow JYY
    Chin Clin Oncol; 2023 Jun; 12(3):27. PubMed ID: 37417291
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for pancreatic Ductal Adenocarcinoma.
    Sekiya S; Fukuda J; Yamamura R; Ooshio T; Satoh Y; Kosuge S; Sato R; Hatanaka KC; Hatanaka Y; Mitsuhashi T; Nakamura T; Matsuno Y; Hirano S; Sonoshita M
    Cancer Res; 2023 Aug; 83(16):2704-2715. PubMed ID: 37378549
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.
    Agrawal R; Natarajan KN
    Adv Cancer Res; 2023; 159():251-283. PubMed ID: 37268398
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21.
    Mortoglou M; Miralles F; Mould RR; Sengupta D; Uysal-Onganer P
    Eur J Cell Biol; 2023 Jun; 102(2):151318. PubMed ID: 37105116
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. pancreatic adenocarcinomas without KRAS, TP53, cdkn2a and SMAD4 mutations and cdkn2a/cdkn2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
    Voutsadakis IA; Digklia A
    Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Single-cell and bulk RNA sequencing identifies T cell marker genes score to predict the prognosis of pancreatic ductal adenocarcinoma.
    Zheng H; Li Y; Zhao Y; Jiang A
    Sci Rep; 2023 Mar; 13(1):3684. PubMed ID: 36878969
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Precision Oncology in pancreatic cancer: Experiences and Challenges of the CCCMunich
    Dorman K; Zhang D; Heinrich K; Reeh L; Weiss L; Haas M; Beyer G; Rössler D; Goni E; Renz BW; D'Haese JG; Kunz WG; Seidensticker M; Corradini S; Niyazi M; Ormanns S; Kumbrink J; Jung A; Klauschen F; Werner J; Mayerle J; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
    Target Oncol; 2023 Mar; 18(2):257-267. PubMed ID: 36853374
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Establishment and Molecular Characterization of Two Patient-Derived pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for treatment Response.
    Braun R; Lapshyna O; Watzelt J; Drenckhan M; Künstner A; Färber B; Hael AAM; Bolm L; Honselmann KC; Konukiewitz B; Castven D; Spielmann M; Gorantla SP; Busch H; Marquardt JU; Keck T; Wellner UF; Ungefroren H
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831254
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized pancreatic Ductal Adenocarcinoma.
    Ecker BL; Tao AJ; Janssen QP; Walch HS; Court CM; Balachandran VP; Crane CH; D'Angelica MI; Drebin JA; Kingham TP; Soares KC; Iacobuzio-Donahue CA; Vakiani E; Gonen M; O'Reilly EM; Varghese AM; Jarnagin WR; Wei AC
    Clin Cancer Res; 2023 Apr; 29(7):1368-1374. PubMed ID: 36795432
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. ASAP1 activates the IQGAP1/CDC42 pathway to promote tumor progression and chemotherapy resistance in gastric cancer.
    Xie W; Han Z; Zuo Z; Xin D; Chen H; Huang J; Zhu S; Lou H; Yu Z; Chen C; Chen S; Hu Y; Huang J; Zhang F; Ni Z; Shen X; Xue X; Lin K
    Cell Death Dis; 2023 Feb; 14(2):124. PubMed ID: 36792578
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 10.